阿托伐他汀对经皮冠状动脉介入术患者心肌损伤的保护作用  

Effect of atorvastatin therapy before percutaneous coronary intervention on periprocedural myocardial injury

作　　者：焦风珍[1] 赵燕[1] 刘晓芳[1] 于春英[1] 

机构地区：[1]烟台市莱阳中心医院心内科,山东省烟台265200

出　　处：《中国基层医药》2011年第24期3348-3349,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 探讨阿托伐他汀对经皮冠状动脉介入术（ PCI）患者心肌损伤的保护作用.方法 285例行PCI患者随机分为观察组（n=140）和对照组（n=145）,两组均按PCI常规治疗,观察组PCI术前7d开始口服阿托伐他汀（40 mg/d）,对照组术前未服用他汀类降脂药.观察两组肌酸激酶同功酶-MB（CK-MB）、肌钙蛋白Ⅰ（TnI）水平变化情况.结果 观察组TnI及CK-MB峰值分别为（0.12±0.26） μg/L、（2.61±3.07）μg/L明显低于对照组的（0.51±1.14） μg/L、（6.85±14.38） μg/L（t=3.951、3.414,均P＜0.05）.结论 PCI术前1周采用阿托伐他汀治疗可减少PCI术后的心肌损伤.Objective To explore the effect of statin in reduction of my ocardial injury in patients undergoing percutaneous coronary intervention（PCI）.Methods Total of 185 patients undergoing PCI were included,140 patients were received atorvastatin before PCI,while 145 were not given statins at the time of PCI.Creatine kinase-MB and troponin Ⅰ were measured at baseline and at 8 and 24 hours after the procedure.Results Post procedurul peak levels of troponin Ⅰ and creatine kinase-MB were（0.12 ±0.26） μg/L and（2.61 ± 3.07） μg/L in the observation group,which were significantly lower than（0.51 ± 1.14） μg/L and（ 6.85 ± 14.38 ） μg/L in the control group（ t =3.951,3.414,P 〈 0.05）.Conclusion Pretreatment with atorvastatin for 7 days could significantly reduces procedural myocardial injury in elective PCI.

关 键 词：血管成形术 经腔 经皮冠状动脉 心肌顿抑 阿托伐他汀 

分 类 号：R541[医药卫生—心血管疾病]